Table 3.

Frequency of Overexpressed ERK1 and ERK5 in Clinically Defined Tumor Subgroups.

HNSCC (N = 306)	n	ERK1	ERK5
T1/2	143	18.3% (20/109)	20.3% (27/133)
vs
T3/4	163	28% (28/100)	34% (49/144)
P		.136	.015
N0	124	18.2% (18/99)	19.3% (22/114)
vs
N1-3	182	27.3% (30/110)	33.1% (54/163)
P		.163	.016
Stages I–III	123	18.0% (16/89)	17.9% (19/106)
vs
Stage IV	183	26.7% (32/120)	33.3% (57/171)
P		.19	.008

P values for univariate subgroup analysis are added. P values ≤ .05 are considered as significant.